Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Lyell Immunopharma stock

Learn how to easily invest in Lyell Immunopharma stock.

Lyell Immunopharma is a biotechnology business based in the US. Lyell Immunopharma shares (LYEL) are listed on the NASDAQ and all prices are listed in US Dollars. Lyell Immunopharma employs 219 staff and has a trailing 12-month revenue of around $39.1 million.

How to buy Lyell Immunopharma stock

  1. Open a stock trading account. Use our comparison table or choose from our Top Picks.
  2. Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
  3. Search for the stock by name or ticker symbol – LYEL. It's that simple.

Best for low fees

Finder Award

SoFi Invest


  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Promoted for easy user experience

Robinhood


  • Commission-free trading
  • Commission-free crypto
  • No minimum account balance

Promoted

tastyworks


  • $0 commissions on stocks and ETFs
  • $0 closing commissions on stock and ETF options
  • Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.

Lyell Immunopharma stock price (NASDAQ: LYEL)

Use our graph to track the performance of LYEL stocks over time.

Lyell Immunopharma shares at a glance

Information last updated 2023-01-25.
Latest market close$3.28
52-week range$2.74 - $8.74
50-day moving average $3.62
200-day moving average $5.45
Wall St. target price$9.00
PE ratio 2.1701
Dividend yield $0 (0%)
Earnings per share (TTM) $1.47

Buy Lyell Immunopharma stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Public.com
Stocks, ETFs, Cryptocurrency, Alternatives
$0
$0
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
$0
$0
N/A
Winner of Finder’s Best Overall Stock Broker award.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Lyell Immunopharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Lyell Immunopharma price performance over time

Historical closes compared with the close of $3.28 from 2023-01-26

1 week (2023-01-20) 9.70%
1 month (2022-12-28) 13.89%
3 months (2022-10-28) -46.32%
6 months (2022-07-28) -41.74%
1 year (2022-01-28) -37.52%
2 years (2021-01-24) N/A
3 years (2020-01-24) N/A
5 years (2018-01-24) N/A

Is Lyell Immunopharma stock undervalued or overvalued?

Valuing Lyell Immunopharma stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Lyell Immunopharma's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Lyell Immunopharma's P/E ratio

Lyell Immunopharma's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 2x. In other words, Lyell Immunopharma shares trade at around 2x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

However, Lyell Immunopharma's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.

    Lyell Immunopharma financials

    Revenue TTM $39.1 million
    Gross profit TTM $10.7 million
    Return on assets TTM -12.57%
    Return on equity TTM -28.61%
    Profit margin 0%
    Book value $3.29
    Market capitalisation $795.3 million

    TTM: trailing 12 months

    Lyell Immunopharma share dividends

    We're not expecting Lyell Immunopharma to pay a dividend over the next 12 months.

    Lyell Immunopharma overview

    Lyell Immunopharma, Inc. , a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

    Frequently asked questions

    What percentage of Lyell Immunopharma is owned by insiders or institutions?
    Currently 15.74% of Lyell Immunopharma shares are held by insiders and 66.096% by institutions.
    How many people work for Lyell Immunopharma?
    Latest data suggests 219 work at Lyell Immunopharma.
    When does the fiscal year end for Lyell Immunopharma?
    Lyell Immunopharma's fiscal year ends in December.
    Where is Lyell Immunopharma based?
    Lyell Immunopharma's address is: 201 Haskins Way, South San Francisco, CA, United States, 94080
    What is Lyell Immunopharma's ISIN number?
    Lyell Immunopharma's international securities identification number is: US55083R1041

    More guides on Finder

    Ask an Expert

    Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

    By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

    Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
    Go to site